Evidence map›Paper›PMID 14989372›Full record

ArticleJournal of investigative medicine : the official publication of the American Federation for Clinical Research2004

Nitric oxide induces apoptosis in spleen lymphocytes from MRL/lpr mice.

Jim C Oates, Gary S Gilkeson

Open access · greenAbstract read
In one paragraph

Article in Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Naja naja atra Venom Protects against Manifestations of Systemic Lupus Erythematosus in MRL/lpr Mice.Evidence-based complementary and alternative medicine : eCAM · 2014
    Article
  4. Article
  5. Review
  6. Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2008
    Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jim C OatesMedical University of South Carolina, Department of Medicine, Division of Rheumatology, 96 Jonathan Lucas Street, Suite 912, PO Box 250637, Charleston, SC 29425, USA. oatesjc@musc.edu
Gary S Gilkeson
Medical University of South Carolina · US

Funding

Role of reactive intermediates in lupus nephritisR01AR045476 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GILKESON, GARY S, OATES, JAMES C · 1999 to 2012
$3.5M
Role of nitric oxide and eicosanoids in lupus nepthritisK08AR002193 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI OATES, JAMES C · 2001 to 2005
$635k
NIAMS NIH HHS AR002193NIAMS NIH HHS AR45476NIAMS NIH HHS K08 AR002193NIAMS NIH HHS R01 AR045476
6 · The paper itself

Abstract

backgroundMRL/MpJ-Tnfrsf6lpr(MRL/lpr) mice, a murine model of systemic lupus erythematosus (SLE), have defective expression of Fas, substantially reducing signaling for apoptosis via this mechanism. However, it is known that MRL/lpr mice have increased spontaneous apoptosis of leukocytes. These conflicting observations have stimulated interest in apoptosis in this SLE model. MRL/lpr mice overproduce nitric oxide (NO) as autoimmune disease progresses. In vitro administration of NO may induce or decrease apoptosis depending on the cell type. Therefore, we hypothesized that NO induces MRL/lpr spleen lymphocyte apoptosis independent of Fas receptor engagement.

methodsPercentages of apoptotic spleen lymphocytes from MRL/lpr and BALB/cJ mice were determined ex vivo after in vivo treatment with NG-monomethyl-L-arginine (NMMA), a nitric oxide synthase (NOS) inhibitor. After culture in varying concentrations of a slow-acting NO donor, the following were determined in spleen lymphocytes: (1) levels of apoptosis, (2) the effect of phorbol myristate acid (PMA) on levels of NO-induced apoptosis, and (3) protein kinase C (PKC) activity.

resultsSpleen lymphocytes from MRL/lpr mice with active disease had increased levels of ex vivo apoptosis when compared with BALB/cJ controls. This increase was reduced by pharmacologic inhibition of NOS in MRL/lpr but not in BALB/cJ mice. Exogenous administration of NO in vitro reduced PKC activity and induced apoptosis in MRL/lpr spleen lymphocytes, an effect that could be reduced via coadministration of PMA in vitro.

conclusionThese results suggest that NO plays a role in spleen lymphocyte apoptosis in MRL/lpr mice, possibly via inhibition of PKC, despite a Fas defect.

Indexed as

AnimalsApoptosisDisease Models, AnimalEnzyme InhibitorsFemaleLupus Erythematosus, SystemicLymphocytesMiceMice, Inbred BALB CMice, Inbred MRL lprNitric Oxideomega-N-MethylarginineSpleenEnzyme InhibitorsNitric Oxideomega-N-Methylarginine

Identifiers

PMID14989372
PMCPMC9733940
OpenAlexW2038927275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.